Covid-19 crisis: Indian drug companies yet to get nod to market remdesivir

The USFDA granted remdesivir an emergency use authorization for the treatment of hospitalized patients with severe Covid-19

While US-based Gilead Sciences has been granted authorisation for restricted emergency use of remdesivir to treat Covid-19 patients, Indian players are yet to receive approval to market the drug.

Moreover, it is learnt that the firms haven’t yet approached the National Pharmaceutical Pricing Regulator (NPPA) formally to discuss pricing of the drug, which will be used on hospitalised patients.

Sources said the pharma companies are in touch with various government departments and there was a video conference meeting recently. However, no decision on pricing has been taken yet. As for dosage, sources say it will be decided by the Indian Council of